Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000541926 | SCV000650053 | pathogenic | Rett syndrome, congenital variant | 2022-02-10 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the FOXG1 protein in which other variant(s) (p.Tyr400*) have been determined to be pathogenic (PMID: 19564653). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 471470). This premature translational stop signal has been observed in individual(s) with epilepsy, gross motor delays and no language abilities (PMID: 24836831). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change creates a premature translational stop signal (p.Gly169Alafs*23) in the FOXG1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 321 amino acid(s) of the FOXG1 protein. |
Ambry Genetics | RCV001267590 | SCV001445772 | pathogenic | Inborn genetic diseases | 2018-09-28 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics Inc | RCV001288608 | SCV001475861 | pathogenic | not provided | 2020-02-20 | criteria provided, single submitter | clinical testing | The variant results in a shift of the reading frame, and is therefore predicted to result in the loss of a functional protein. Found in at least one patient with expected phenotype for this gene, and found in general population data at a frequency that is consistent with pathogenicity. |
Gene |
RCV001288608 | SCV001791914 | pathogenic | not provided | 2022-06-06 | criteria provided, single submitter | clinical testing | Reported previously in a patient with myoclonic seizures, tonic seizures, and drop seizures (Seltzer et al., 2014); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 27640358, 25356899, 24836831, 30792901, 33644862, 34788679) |
Institute of Human Genetics, |
RCV000541926 | SCV002026233 | pathogenic | Rett syndrome, congenital variant | 2018-01-20 | criteria provided, single submitter | clinical testing | |
Institute Of Human Genetics Munich, |
RCV000541926 | SCV002764708 | pathogenic | Rett syndrome, congenital variant | 2021-12-13 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000541926 | SCV004801467 | pathogenic | Rett syndrome, congenital variant | 2017-04-28 | criteria provided, single submitter | clinical testing | The FOXG1 c.506delG p.(Gly169AlafsTer23) variant causes a shift in the protein reading frame that is predicted to result in premature termination of the protein. Loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay is expected. This variant has been identified in a de novo state in individuals with a phenotype consistent with Rett syndrome, congenital variant (Seltzer et al. 2014; Hamdan et al. 2014). This variant is not observed in version 2.1.1 of the Genome Aggregation Database. The variant was identified in a de novo state in the proband. Based on the available evidence, the c.506delG p.(Gly169AlafsTer23) variant is classified as pathogenic for Rett syndrome, congenital variant. |
Service de Génétique Moléculaire, |
RCV000541926 | SCV001432346 | pathogenic | Rett syndrome, congenital variant | no assertion criteria provided | clinical testing | ||
Kasturba Medical College, |
RCV000541926 | SCV001787118 | pathogenic | Rett syndrome, congenital variant | no assertion criteria provided | clinical testing |